Last reviewed · How we verify
Intracytoplasmic sperm injection
At a glance
| Generic name | Intracytoplasmic sperm injection |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens (NA)
- Biomarkers of Endometrial Receptivity (NA)
- Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
- Association Between Serum Thyroid-stimulating Hormone (TSH) and Intracytoplasmic Sperm Injection (ICSI) Outcome in Women Undergoing ICSI
- Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia (NA)
- Zona Pellucida Bound Sperm vs. Embryologist Selected Sperm for Intracytoplasmic Sperm Injection (NA)
- 150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial (PHASE3)
- Evaluating the Safety and Clinical Efficacy of the BAIBYS™ System in Intracytoplasmic Sperm Injection (ICSI) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intracytoplasmic sperm injection CI brief — competitive landscape report
- Intracytoplasmic sperm injection updates RSS · CI watch RSS
- Cairo University portfolio CI